Arsanis has recently initiated a Phase 1 study of its lead product candidate, ASN100, a novel antibody combination designed to prevent and treat serious Staphylococcus aureus infections
Arsanis recruited Dr. Rene Russo (former VP of Global Medical Affairs at Cubist) as Chief Development Officer.
Arsanis opens a Boston office and builds a clinical development team.